Regulation of Human MAPT Gene Expression

Overview

Journal Mol Neurodegener

Publisher Biomed Central

Specialties Molecular Biology
Neurology

Date 2015 Jul 15

PMID 26170022

Citations 92

Authors

Marie-Laure Caillet-Boudin

Luc Buee

Nicolas Sergeant

Bruno Lefebvre

Affiliations

Soon will be listed here.

Abstract

The number of known pathologies involving deregulated Tau expression/metabolism is increasing. Indeed, in addition to tauopathies, which comprise approximately 30 diseases characterized by neuronal aggregation of hyperphosphorylated Tau in brain neurons, this protein has also been associated with various other pathologies such as cancer, inclusion body myositis, and microdeletion/microduplication syndromes, suggesting its possible function in peripheral tissues. In addition to Tau aggregation, Tau deregulation can occur at the expression and/or splicing levels, as has been clearly demonstrated in some of these pathologies. Here, we aim to review current knowledge regarding the regulation of human MAPT gene expression at the DNA and RNA levels to provide a better understanding of its possible deregulation. Several aspects, including repeated motifs, CpG island/methylation, and haplotypes at the DNA level, as well as the key regions involved in mRNA expression and stability and the splicing patterns of different mRNA isoforms at the RNA level, will be discussed.

Citing Articles

DNA methylation as a contributor to dysregulation of and other frontotemporal lobar degeneration genetic risk-associated loci.

Rambarack N, Fodder K, Murthy M, Toomey C, de Silva R, Heutink P bioRxiv. 2025; .

PMID: 39975316 PMC: 11838521. DOI: 10.1101/2025.01.21.634065.

Associations Between Diabetes Mellitus and Neurodegenerative Diseases.

Szablewski L Int J Mol Sci. 2025; 26(2).

PMID: 39859258 PMC: 11765393. DOI: 10.3390/ijms26020542.

Regulatory roles of eugenol in paraquat-altered SNCA/LZTS3/MAPT in the cerebellum of Wistar rats.

Uchewa O, Ibegbu A, Okafor S, Nwafor J, Egwu O Lab Anim Res. 2025; 41(1):2.

PMID: 39810258 PMC: 11734554. DOI: 10.1186/s42826-025-00236-8.

The MIR-NAT MAPT-AS1 does not regulate Tau expression in human neurons.

Policarpo R, Wolfs L, Martinez-Montero S, Vandermeulen L, Royaux I, Van Peer G PLoS One. 2025; 20(1):e0314973.

PMID: 39761259 PMC: 11703057. DOI: 10.1371/journal.pone.0314973.

Accumulation of microtubule-associated protein tau promotes hepatocellular carcinogenesis through inhibiting autophagosome-lysosome fusion.

Liu X, Hao Z, He H, Wang X, Wang W, Shu X Mol Cell Biochem. 2024; .

PMID: 39718681 DOI: 10.1007/s11010-024-05193-9.

References

Cirak Y, Sarsik B, Cakar B, Sen S, Simsir A, Uslu R . Predictive and prognostic values of Tau and BubR1 protein in prostate cancer and their relationship to the Gleason score. Med Oncol. 2013; 30(2):526. DOI: 10.1007/s12032-013-0526-7. View

Mackenzie I, Neumann M, Bigio E, Cairns N, Alafuzoff I, Kril J . Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol. 2008; 117(1):15-8. PMC: 2710877. DOI: 10.1007/s00401-008-0460-5. View

Aranda-Abreu G, Behar L, Chung S, Furneaux H, Ginzburg I . Embryonic lethal abnormal vision-like RNA-binding proteins regulate neurite outgrowth and tau expression in PC12 cells. J Neurosci. 1999; 19(16):6907-17. PMC: 6782881. View

Kanaan N, Morfini G, LaPointe N, Pigino G, Patterson K, Song Y . Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. J Neurosci. 2011; 31(27):9858-68. PMC: 3391724. DOI: 10.1523/JNEUROSCI.0560-11.2011. View

Caillet-Boudin M, Fernandez-Gomez F, Tran H, Dhaenens C, Buee L, Sergeant N . Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy. Front Mol Neurosci. 2014; 6:57. PMC: 3885824. DOI: 10.3389/fnmol.2013.00057. View

Andreadis A . Tau splicing and the intricacies of dementia. J Cell Physiol. 2011; 227(3):1220-5. PMC: 3177961. DOI: 10.1002/jcp.22842. View

Goedert M, Ghetti B, Spillantini M . Frontotemporal dementia: implications for understanding Alzheimer disease. Cold Spring Harb Perspect Med. 2012; 2(2):a006254. PMC: 3281593. DOI: 10.1101/cshperspect.a006254. View

Sultan A, Nesslany F, Violet M, Begard S, Loyens A, Talahari S . Nuclear tau, a key player in neuronal DNA protection. J Biol Chem. 2010; 286(6):4566-75. PMC: 3039398. DOI: 10.1074/jbc.M110.199976. View

Strausberg R, Feingold E, Grouse L, Derge J, Klausner R, Collins F . Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A. 2002; 99(26):16899-903. PMC: 139241. DOI: 10.1073/pnas.242603899. View

10.

Caffrey T, Joachim C, Wade-Martins R . Haplotype-specific expression of the N-terminal exons 2 and 3 at the human MAPT locus. Neurobiol Aging. 2007; 29(12):1923-9. PMC: 2801070. DOI: 10.1016/j.neurobiolaging.2007.05.002. View

11.

Santa-Maria I, Haggiagi A, Liu X, Wasserscheid J, Nelson P, Dewar K . The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol. 2012; 124(5):693-704. PMC: 3608475. DOI: 10.1007/s00401-012-1017-1. View

12.

Aronov S, Marx R, Ginzburg I . Identification of 3'UTR region implicated in tau mRNA stabilization in neuronal cells. J Mol Neurosci. 1999; 12(2):131-45. DOI: 10.1007/BF02736927. View

13.

Poorkaj P, Kas A, DSouza I, Zhou Y, Pham Q, Stone M . A genomic sequence analysis of the mouse and human microtubule-associated protein tau. Mamm Genome. 2001; 12(9):700-12. DOI: 10.1007/s00335-001-2044-8. View

14.

Goedert M, Spillantini M, Jakes R, Rutherford D, Crowther R . Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron. 1989; 3(4):519-26. DOI: 10.1016/0896-6273(89)90210-9. View

15.

Steffensen K, Smoter M, Waldstrom M, Grala B, Bodnar L, Stec R . Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression. Int J Oncol. 2014; 44(5):1736-44. DOI: 10.3892/ijo.2014.2311. View

16.

Karolchik D, Barber G, Casper J, Clawson H, Cline M, Diekhans M . The UCSC Genome Browser database: 2014 update. Nucleic Acids Res. 2013; 42(Database issue):D764-70. PMC: 3964947. DOI: 10.1093/nar/gkt1168. View

17.

Pittman A, Myers A, Duckworth J, Bryden L, Hanson M, Abou-Sleiman P . The structure of the tau haplotype in controls and in progressive supranuclear palsy. Hum Mol Genet. 2004; 13(12):1267-74. DOI: 10.1093/hmg/ddh138. View

18.

Li L, Dahiya R . MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002; 18(11):1427-31. DOI: 10.1093/bioinformatics/18.11.1427. View

19.

Sergeant N, Delacourte A, Buee L . Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta. 2004; 1739(2-3):179-97. DOI: 10.1016/j.bbadis.2004.06.020. View

20.

Cohen J, Lee P, Fields R . Systematic identification of 3'-UTR regulatory elements in activity-dependent mRNA stability in hippocampal neurons. Philos Trans R Soc Lond B Biol Sci. 2014; 369(1652). PMC: 4142030. DOI: 10.1098/rstb.2013.0509. View